|
|
| Mumps, IgG Antibody Detection | ||
| Order Code: MUMP
Order Form: A-1a Clinical Microbiology Laboratory or IPR Req |
Microbiology BT 6004 356-2591 (0700-2300)Bacteriology/Virology Section 356-3527 (2300-0700) Core Lab |
|
Specimen |
Serum | ||
Collection Medium: |
| ||
Minimum: |
2 ml; red top tube (no additive) | ||
Testing Schedule: |
Test performed twice weekly. | ||
Analytic Time: |
3 days | ||
Reference Range: |
Negative | ||
Test Limitations: |
This test is a qualitative enzyme-linked fluorescent immunoassay (ELFA) for the detection of IgG antibodies to mumps virus to provide a means of determining the immune status of individuals. Mumps is a paramyxovirus that causes an acute generalized infection primarily in children and adolescents (1). Mumps is usually a self-limited, benign infection with one-third of infected individuals remaining asymptomatic, however, complications (meningitis, encephalitis, epididymo-orchitis, oophoritis, et al) may occur (1). A mumps vaccine used in the U.S. since 1967 is credited with a >99% drop in the annual number of cases documented in 1996 (2). A negative mumps IgG test result indicates possible susceptibility to mumps infection. If a patient has an equivocal result, a new specimen will be requested for repeat testing. A positive test result indicates prior exposure to mumps (usually by vaccination) or a convalescent stage of infection. A false positive result is possible due to cross-reactions with other paramyxoviruses (i.e., parainfluenza viruses) (3). Positive results in patients that have received blood products within the past 3 months may not indicate the patient's true immune status. References 1) Baum SG and N Litman. 2000. "Mumps virus." In G.M. Mandell., J.E. Bennett, & R. Dolin. (Eds.) Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. (pp. 1776- 1781). Philadelphia, PA: Churchill Livingstone. 2) Centers for Disease Control and Prevention. 1997. Status report on the childhood immunization initiative: reported cases of selected vaccine-preventable diseases-United States, 1996. MMWR 46:665-671. 3) Harmsen T, et al. 1992. Comparison of a neutralization enzyme immunoassay for evaluation of immune status of children vaccinated for mumps. J Clin Microbiol 30:2139-2144. | ||
Methodology: |
Enzyme-Linked Fluorescent Immunoassay (ELFA) | ||
CPT Code: |
86735 | ||
See Additional Information: Microbiology Specimen Collection and Transport |
Updated: 06/06/2007
Note: The information contained in this handbook is for use by personnel of University of Iowa Health Care. No other use is implied or intended.